Finishing what we started, QuidelOrtho (NASDAQ: QDEL) completes $100 million acquisition

QuidelOrtho Corporation (NASDAQ: QDEL) completed its acquisition of LEX Diagnostics for approximately $100 million in cash, the company announced. 

The acquisition brings QuidelOrtho the LEX VELO System, a molecular diagnostics platform that delivers RT-PCR testing for Influenza A, Influenza B, and COVID-19 from swab samples in six to ten minutes. The system received U.S. Food and Drug Administration 510(k) clearance and CLIA waiver in February 2026. 

The LEX VELO System uses a cartridge-based design that eliminates the need for external liquid handling. The platform is designed for decentralized care environments and provides multiplex testing capabilities. 

“This ultra-fast PCR platform is designed to deliver lab-quality results in minutes and fits seamlessly into point-of-care workflows,” said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho.